FDA Grants Orphan Drug Designation for MediGene's Drug Candidate EndoTAG(TM)-1
Orphan drug designation ensures market exclusivity for a period of seven years following market approval
25-May-2009 -
MediGene AG has obtained orphan drug designation from the US regulatory authority FDA (US Food and Drug Administration) for paclitaxel, the active ingredient in MediGene's drug candidate EndoTAG(TM)-1 for the indication pancreatic cancer. Orphan drug designation for EndoTAG(TM)-1 in this ...
MediGene
Orphan Drug Designation
pancreatic cancer